Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

Inclusion Criteria: 1. Age 19+ 2. Patients treated with a new generation of Evelorimus-eluting stents (Synergy®) 3. Patients who understand the content of the subject description and voluntarily sign the subject Exclusion Criteria: 1. Age 86+ 2. Hemodynamically unstable patient 3. Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus, contrast agent 4. Patients at high risk of bleeding, anemia, thrombocytopenia 5. Patients requiring oral anticoagulants 6. Pregnant women or women of childbearing age 7. Life expectancy is less than one year 8. Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin, napjodone, ritonavir, atazanavir) 9. Patients with a history of intracranial hemorrhage 10. Patients with moderate to severe hepatic impairment 11. Patients underwent coronary intervention with stenting within 1 year 12. Patients with left-main lesions requiring coronary intervention 13. Patients with chronic stricture lesions requiring treatment 14. Patients with in-stent restenosis in a lesion requiring treatment 15. Patients with bifurcation lesions requiring stenting in lateral branches 16. Patients with lesions requiring more than 3 stents